Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Chronic Insomnia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT00656994
First received: March 12, 2008
Last updated: February 27, 2012
Last verified: February 2012
  Purpose

The purpose of this study is to determine the long-term effects of Ramelteon, once daily (QD), on endocrine function values.


Condition Intervention Phase
Insomnia
Drug: Ramelteon
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Safety Study to Evaluate the Long-term Effects of TAK-375 on Endocrine Function in Adult Subjects With Chronic Insomnia

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change from baseline in Total Serum Thyroxine. [ Time Frame: Months 1, 2, 3, 4, 5, and 6 or Final Visit ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Change from baseline in free thyroxine. [ Time Frame: Months 1, 2, 3, 4, 5, and 6 or Final Visit ] [ Designated as safety issue: Yes ]
  • Change from baseline in thyroid stimulating hormone. [ Time Frame: Months 1, 2, 3, 4, 5, and 6 or Final Visit ] [ Designated as safety issue: Yes ]
  • Change from baseline in triiodothyronine. [ Time Frame: Months 1, 2, 3, 4, 5, and 6 or Final Visit ] [ Designated as safety issue: Yes ]
  • Change from baseline in total testosterone (men only). [ Time Frame: Months 1, 2, 3, 4, 5, and 6 or Final Visit ] [ Designated as safety issue: Yes ]
  • Change from baseline in free testosterone (men only). [ Time Frame: Months 1, 2, 3, 4, 5, and 6 or Final Visit ] [ Designated as safety issue: Yes ]
  • Change from baseline in estradiol (women only). [ Time Frame: Months 1, 2, 3, 4, 5, and 6 or Final Visit ] [ Designated as safety issue: Yes ]
  • Change from baseline in prolactin. [ Time Frame: Months 1, 2, 3, 4, 5, and 6 or Final Visit ] [ Designated as safety issue: Yes ]
  • Change from baseline in follicle stimulating hormone (women only). [ Time Frame: Months 1, 2, 3, 4, 5, and 6 or Final Visit ] [ Designated as safety issue: Yes ]
  • Change from baseline in luteinizing hormone (women only). [ Time Frame: Months 1, 2, 3, 4, 5, and 6 or Final Visit ] [ Designated as safety issue: Yes ]
  • Change from baseline in luteinizing hormone surge (women only) [ Time Frame: Months 1, 2, 3, 4, 5, and 6 or Final Visit ] [ Designated as safety issue: Yes ]
  • Change from baseline in adrenocorticotropic hormone. [ Time Frame: Months 1, 2, 3, 4, 5, and 6 or Final Visit ] [ Designated as safety issue: Yes ]
  • Change from baseline in cortisol (AM). [ Time Frame: Months 1, 2, 3, 4, 5, and 6 or Final Visit ] [ Designated as safety issue: Yes ]
  • Change from baseline in adrenocorticotropic hormone stimulation test. [ Time Frame: Month 6 or Final Visit ] [ Designated as safety issue: Yes ]

Enrollment: 122
Study Start Date: January 2003
Study Completion Date: July 2004
Primary Completion Date: July 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ramelteon 16 mg QD Drug: Ramelteon
Ramelteon 16 mg, tablets, orally, once nightly for up to 6 months.
Other Names:
  • Ramelteon
  • Rozerem
  • TAK-375
Placebo Comparator: Placebo Drug: Placebo
Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months

Detailed Description:

Insomnia is characterized by a complaint of either difficulties initiating and maintaining sleep or of nonrestorative and non-refreshing sleep. Transient insomnia affects approximately one-third to one-half of the US population, based on the results of 2 surveys of representative samples of the adult US population conducted by the Gallup Organization in which respondents were asked if they had "ever had difficulty sleeping." Based on reports of "regular" or "frequent" sleep difficulty, results from the same studies suggest that approximately one-tenth of the US population experiences chronic insomnia. The ideal treatment for insomnia would reduce the latency to onset of sleep and increase total sleep time, without a negative impact on sleep architecture and without safety concerns or next-day effects.

Ramelteon is a melatonin-1 receptor agonist under global development by Takeda Chemical Industries, Ltd., Osaka, Japan, for the treatment of transient and chronic insomnia and for the treatment of Circadian Rhythm Sleep Disorders.

This study has been designed to determine the long-term (6 month) effects of Ramelteon on endocrine function values. Study participation is anticipated to be about 7 months.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  • Has had primary insomnia as defined by the Diagnostic and Statistical Manual of Mental Disorders, Text Revision for at least 3 months and a history of daytime complaint(s) associated with disturbed sleep.
  • Has a subjective sleep latency (sSL) greater than or equal to 45 minutes and a subjective total sleep time less than or equal to 6.5 hours for at least 3 nights out of one week.
  • Habitual bedtime is between 8:30PM and 12:00AM.
  • Habitual awakening time is between 5:00 AM and 10:00 AM.
  • Male and female subjects must have serum prolactin, luteinizing hormone, follicle stimulating hormone, adrenocorticotropic hormone, thyroid stimulating hormone, triiodothyronine and thyroxine within normal range. Normal ranges for luteinizing hormone and follicle stimulating hormone for female subjects will be defined as the lowest value among the menstrual phases to the highest value among the menstrual phases.
  • Body mass index between 18 and 34, inclusive.
  • Male subjects must have serum testosterone values of greater than or equal to 150 ng per dL.
  • Female subjects must have serum estradiol values within normal range.

Exclusion Criteria

  • Known hypersensitivity to ramelteon or related compounds, including melatonin.
  • Previously participated in a study involving ramelteon.
  • Participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to Day 1, whichever is longer.
  • Sleep schedule changes required by employment (eg, shift worker) within three months prior to Day 1, or has flown across greater than three time zones within seven days prior to screening.
  • Participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to Day 1.
  • Ever had a history of seizures, sleep apnea, chronic obstructive pulmonary disease, restless leg syndrome, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.
  • History of psychiatric disorder (including anxiety or depression) within the past 12 months.
  • History of drug addiction or drug abuse within the past 12 months.
  • History of alcohol abuse within the past 12 months, as defined in Diagnostic and Statistical Manual of Mental Disorders, Text Revision and/or regularly consumes 4 or more alcoholic drinks per day.
  • Current significant neurological (including psychiatric and cognitive disorders), hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, or metabolic disease, unless currently controlled and stable with protocol-allowed medication 30 days prior to Day 1.
  • Uses tobacco products during nightly awakenings.
  • Used melatonin, or other drugs or supplements known to affect sleep/wake function within 1week (or 5 half lives of the drug, whichever is longer) prior to Day 1.
  • Used any central nervous system medication within 1 week (or 5 half lives of the drug, whichever is longer) prior to Day 1. These medications must not have been used to treat psychiatric disorders.
  • Any clinically important abnormal finding as determined by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.
  • Positive hepatitis panel including anti- hepatitis A virus (only immunoglobulin M is exclusionary), anti- hepatitis B surface (except in subjects who have received hepatitis B virus vaccination), hepatitis B surface antigen, anti-hepatitis B core (only immunoglobulin M is exclusionary), or anti-hepatitis C virus..
  • Any significant endocrine pathology based on borderline laboratory results.
  • Any additional condition(s) that in the Investigator's opinion would:

    • affect endocrine function (eg, hyperthyroidism, diabetes)
    • prohibit the subject from completing the study, or
    • not be in the best interest of the subject to participate in the study.
  • Morning serum cortisol at the Screening visit of less than 7.0 μg per dl.
  • Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • anxiolytics
    • hypnotics
    • antidepressants
    • anticonvulsants
    • sedating H1 antihistamines
    • systemic steroids
    • respiratory stimulants (eg, theophylline) and decongestants
    • over-the-counter and prescription stimulants
    • over-the-counter and prescription diet aids
    • central nervous system active drugs
    • narcotic analgesics
    • beta blockers
    • St. John's Wort
    • kava-kava
    • gingko biloba
    • melatonin
    • other drugs or supplements known to affect sleep/wake function.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00656994

  Show 29 Study Locations
Sponsors and Collaborators
Takeda
Investigators
Study Director: VP Clinical Science Takeda
  More Information

Additional Information:
Publications:
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT00656994     History of Changes
Other Study ID Numbers: 01-02-TL-375-032, U1111-1114-2594
Study First Received: March 12, 2008
Last Updated: February 27, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Sleep Disorder
Insomnia

Additional relevant MeSH terms:
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Disorders
Nervous System Diseases
Mental Disorders

ClinicalTrials.gov processed this record on August 28, 2014